Alnylam Pharmaceuticals Executive and Leadership Team

Jeff Poulton, the Chief Financial Officer at Alnylam Pharmaceuticals, directs all global financial operations and capital allocation strategies. Overseeing fiscal planning, the Chief Financial Officer ensures the company maintains sufficient liquidity to fund extensive research and development programs for RNAi therapeutics. This leadership role involves managing investor relations and optimizing the balance sheet to support long-term growth across North American and international markets. By aligning financial resources with clinical milestones, Jeff Poulton directly impacts the ability of the organization to bring innovative treatments like ONPATTRO and GIVLAARI to patients. Poulton secures the necessary capital to sustain the aggressive development of the pipeline, including programs for hypertension and Alzheimer's disease. Through rigorous financial oversight, the Chief Financial Officer maintains the fiscal health required to navigate complex biopharmaceutical market dynamics and deliver consistent value to shareholders while advancing the core mission of the company.

Vasant Jadhav, the Chief Technology Officer at Alnylam Pharmaceuticals, architects the technical infrastructure and scientific platforms driving RNAi discovery. Overseeing the integration of advanced delivery technologies, the Chief Technology Officer ensures the company remains at the forefront of genetic medicine. This leadership role involves managing collaborations with partners like Regeneron and Roche to expand the therapeutic reach of RNAi into the eye and central nervous system. By optimizing the platform for diverse disease targets, Vasant Jadhav directly impacts the efficiency of the drug development lifecycle. Jadhav drives the technical innovation necessary to transition candidates from early-stage research into phase 3 clinical trials. Through the application of cutting-edge molecular biology, the Chief Technology Officer maintains a competitive edge in the biopharmaceutical industry. This focus on technical excellence supports the development of therapies for conditions ranging from chronic HBV infection to NASH, ensuring the company continues to lead in the field of ribonucleic acid interference.

Shweta Randeria, the Chief Marketing Officer at Alnylam Pharmaceuticals, directs the commercial strategy and market access initiatives for the entire portfolio of marketed products. Overseeing global brand positioning, the Chief Marketing Officer ensures that therapies like AMVUTTRA and OXLUMO reach the patients who need them most. This leadership role involves coordinating with regional teams to navigate complex healthcare landscapes and secure reimbursement for rare disease treatments. By executing data-driven marketing campaigns, Shweta Randeria directly impacts the adoption rates of RNAi therapeutics in clinical practice. Randeria manages the commercialization efforts that translate scientific breakthroughs into tangible patient benefits across diverse therapeutic areas. Through strategic engagement with healthcare providers and patient advocacy groups, the Chief Marketing Officer builds awareness for hereditary transthyretin-mediated amyloidosis and other conditions. This focus on commercial excellence ensures the company successfully scales its market presence while maintaining a deep commitment to the patient community and the broader medical ecosystem.

Carlo Cristobal, the Head To of & Ttr Franchise Chief of Staff (US) at Alnylam Pharmaceuticals, coordinates the operational execution of the TTR franchise across the United States. Overseeing cross-functional alignment, the Head To of & Ttr Franchise Chief of Staff (US) ensures that clinical and commercial objectives for ATTR amyloidosis treatments remain synchronized. This leadership role involves streamlining internal processes to accelerate the delivery of vutrisiran and other key assets to the market. By facilitating communication between departments, Carlo Cristobal directly impacts the operational efficiency of the franchise. Cristobal manages the strategic initiatives that support the growth of the TTR portfolio, ensuring that the company meets its clinical trial milestones and commercial targets. Through the implementation of robust project management frameworks, the Head To of & Ttr Franchise Chief of Staff (US) drives the successful execution of the franchise strategy. This focus on operational precision supports the overall mission of providing life-changing therapies to patients suffering from transthyretin-mediated diseases.

Melissa McLaughlin, the Chief Human Resources Officer at Alnylam Pharmaceuticals, directs the talent acquisition, organizational development, and culture-building initiatives for the global workforce. Overseeing human capital strategy, the Chief Human Resources Officer ensures the company attracts and retains the scientific and commercial talent necessary to sustain its leadership in RNAi therapeutics. This leadership role involves fostering an inclusive environment that encourages innovation and collaboration across all departments. By implementing comprehensive professional development programs, Melissa McLaughlin directly impacts the engagement and productivity of the team. McLaughlin manages the organizational structure to support the rapid growth of the company as it expands its clinical pipeline and commercial footprint. Through the alignment of human resources policies with corporate goals, the Chief Human Resources Officer maintains a high-performance culture. This focus on talent management ensures the organization possesses the human capital required to solve complex biological challenges and deliver on the promise of genetic medicine for patients worldwide.

Danielle Dougherty, the Manager, Chief Marketing Officer Management at Alnylam Pharmaceuticals, directs the administrative and operational workflows supporting the commercial leadership team. Overseeing the coordination of marketing projects, the Manager, Chief Marketing Officer Management ensures that the commercial department operates with maximum efficiency. This leadership role involves managing the internal communications and resource allocation for the marketing division. By optimizing the daily operations of the commercial team, Danielle Dougherty directly impacts the speed and effectiveness of product launches and market expansion efforts. Dougherty manages the logistical support required for the successful promotion of the company's portfolio of RNAi therapeutics. Through the implementation of streamlined administrative processes, the Manager, Chief Marketing Officer Management facilitates the execution of the broader commercial strategy. This focus on operational support ensures that the marketing leadership can concentrate on high-level strategic initiatives, ultimately contributing to the successful delivery of innovative treatments to patients suffering from rare genetic diseases.

Bryan Supran, the Chief Legal Officer at Alnylam Pharmaceuticals, directs the legal, compliance, and intellectual property strategies that protect the company's innovative RNAi platform. Overseeing the management of complex license and collaboration agreements, the Chief Legal Officer ensures the company maintains strong partnerships with entities like Novartis and Vir Biotechnology. This leadership role involves navigating the regulatory landscape to secure the rights to develop and commercialize novel therapeutics. By mitigating legal risks and defending the patent portfolio, Bryan Supran directly impacts the long-term viability of the company's drug development programs. Supran manages the legal framework that supports the expansion of the pipeline into new therapeutic areas such as hypertension and Alzheimer's disease. Through the provision of strategic legal counsel, the Chief Legal Officer ensures that all business activities align with global regulatory standards. This focus on legal integrity supports the company's mission to pioneer genetic medicine while maintaining a secure and sustainable business model.